About: Alveolar lipids in pulmonary disease. A review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Alveolar lipids in pulmonary disease. A review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Alveolar lipids in pulmonary disease. A review
Creator	Agudelo, Christina Garcia-Arcos, Itsaso Samaha, Ghassan
Source	Medline; PMC
abstract	Lung lipid metabolism participates both in infant and adult pulmonary disease. The lung is composed by multiple cell types with specialized functions and coordinately acting to meet specific physiologic requirements. The alveoli are the niche of the most active lipid metabolic cell in the lung, the type 2 cell (T2C). T2C synthesize surfactant lipids that are an absolute requirement for respiration, including dipalmitoylphosphatidylcholine. After its synthesis and secretion into the alveoli, surfactant is recycled by the T2C or degraded by the alveolar macrophages (AM). Surfactant biosynthesis and recycling is tightly regulated, and dysregulation of this pathway occurs in many pulmonary disease processes. Alveolar lipids can participate in the development of pulmonary disease from their extracellular location in the lumen of the alveoli, and from their intracellular location in T2C or AM. External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD), and others. Sustained damage to the T2C is one of the postulated causes of idiopathic pulmonary fibrosis (IPF), and surfactant homeostasis is disrupted during fibrotic conditions. Similarly, surfactant homeostasis is impacted during acute respiratory distress syndrome (ARDS) and infections. Bioactive lipids like eicosanoids and sphingolipids also participate in chronic lung disease and in respiratory infections. We review the most recent knowledge on alveolar lipids and their essential metabolic and signaling functions during homeostasis and during some of the most commonly observed pulmonary diseases.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1186/s12944-020-01278-8
bibo:pmid	32493486
has license	cc-by
sha1sum (hex)	82204a9701acb01ef25d9bd2901551efa215c4b2
schema:url	https://doi.org/10.1186/s12944-020-01278-8
resource representing a document's title	Alveolar lipids in pulmonary disease. A review
has PubMed Central identifier	PMC7268969
has PubMed identifier	32493486
schema:publication	Lipids Health Dis
resource representing a document's body	covid:82204a9701acb01ef25d9bd2901551efa215c4b2#body_text
is schema:about of	named entity 'processes' named entity 'observed' named entity 'insults' named entity 'infections' named entity 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE' named entity 'ALVEOLAR MACROPHAGES' named entity 'DEVELOPMENT' named entity 'PHYSIOLOGIC' named entity 'PROCESSES' named entity 'SIGNALING' named entity 'BUT' named entity 'participate' named entity 'recycled' named entity 'lumen' named entity 'IPF' named entity 'lipids' named entity 'pulmonary disease' named entity 'lipids' named entity 'development' named entity 'conditions' named entity 'alveolar' named entity 'lung' named entity 'metabolic' named entity 'chronic' named entity 'participate' named entity 'biosynthesis' named entity 'respiration' named entity 'pulmonary diseases' named entity 'chronic lung disease' named entity 'respiratory infections' named entity 'pulmonary disease' named entity 'homeostasis' named entity 'homeostasis' named entity 'Surfactant' named entity 'IPF' named entity 'intracellular' named entity 'lipids' named entity 'metabolic' named entity 'surfactant' named entity 'Lung' named entity 'cell types' named entity 'homeostasis' named entity 'lipids' named entity 'alveolar macrophages' named entity 'pulmonary disease' named entity 'observed' named entity 'surfactant' named entity 'vaping' named entity 'angiotensin' named entity 'cholesterol' named entity 'SP-C' named entity 'intracellular' named entity 'maresins' named entity '21 days' named entity 'knockout mice' named entity 'gas exchange' named entity 'IRDS' named entity 'phosphatidylglycerol' named entity 'fibrosis' named entity 'amiodarone' named entity 'Leukotriene' named entity 'Cholesterol' named entity 'carbon monoxide' named entity 'collagen' named entity 'metabolism' named entity 'sphingosine' named entity 'alveolar macrophages' named entity 'exogenous' named entity 'LOX' named entity 'downregulation' named entity 'Survanta' named entity 'lamellar bodies' named entity 'surface tension' named entity 'lipid' named entity 'alveolar macrophages' named entity 'cholesterol' named entity 'intracellular' named entity 'surfactant' named entity 'fibrosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software